Daily Respiratory Research Analysis
Three impactful respiratory studies span implementation, translational, and clinical oncology. A validated electronic quality measure accurately detects postoperative respiratory failure from EHR data, enabling scalable quality improvement. A mechanistic study introduces zinc-binding inhibitors of Legionella pneumophila ProA as pathoblockers, while a multi-institutional cohort shows durvalumab after chemoradiation prolongs PFS in EGFR-mutant stage III NSCLC.
Summary
Three impactful respiratory studies span implementation, translational, and clinical oncology. A validated electronic quality measure accurately detects postoperative respiratory failure from EHR data, enabling scalable quality improvement. A mechanistic study introduces zinc-binding inhibitors of Legionella pneumophila ProA as pathoblockers, while a multi-institutional cohort shows durvalumab after chemoradiation prolongs PFS in EGFR-mutant stage III NSCLC.
Research Themes
- Automated quality measurement for postoperative respiratory failure
- Pathoblocking virulence in bacterial pneumonia
- Consolidation immunotherapy after chemoradiation in EGFR-mutated stage III NSCLC
Selected Articles
1. Development and validation of an electronic quality measure for postoperative respiratory failure.
Across 12 hospitals using two EHR vendors, an electronic clinical quality measure accurately identified postoperative respiratory failure with PPV 88.7% and NPV 99.7%. A risk model (c-statistic 0.91) enabled risk-adjusted rates (0.0–16.8/1,000 hospitalizations), and most false positives stemmed from correctable documentation errors.
Impact: Provides a validated, scalable eCQM to detect postoperative respiratory failure directly from structured EHR data, reducing reliance on manual abstraction and claims.
Clinical Implications: Hospitals can monitor postoperative respiratory failure reliably in near real-time, benchmark performance, and target quality improvement (eg, ventilator management, extubation protocols) while correcting documentation practices to reduce false positives.
Key Findings
- Electronic measure achieved PPV 88.7% and NPV 99.7% for postoperative respiratory failure.
- Risk model demonstrated excellent discrimination (c-statistic 0.91) and produced risk-adjusted hospital rates (0.0–16.8/1,000).
- False positives were commonly due to fixable respiratory therapist documentation errors.
Methodological Strengths
- Multicenter validation across 12 hospitals and two EHR vendors with standardized chart abstraction.
- High predictive validity (PPV/NPV) and strong risk model discrimination (c-statistic 0.91).
Limitations
- Retrospective design limited to structured data from 2022 and 12 hospitals; generalizability may vary.
- Residual dependence on documentation accuracy; some false positives reflect recording practices.
Future Directions: Prospective deployment at scale with feedback loops to reduce documentation errors; linkage to patient outcomes and cost to quantify QI impact; interoperability testing across additional EHR ecosystems.
BACKGROUND: Postoperatively, prolonged mechanical ventilation or unplanned intubation-collectively, "postoperative respiratory failure"-has high morbidity and mortality risk, but hospitals' automated ability to detect this complication is currently limited. STUDY DESIGN: We developed an electronic clinical quality measure for postoperative respiratory failure on the basis of input from clinical and quality experts. Using 2022 structured electronic health record data from 12 diverse hospitals encompassing 2 common electronic health record vendors, we retrospe
2. Innovative zinc-binding inhibitors of Legionella pneumophila ProA reduce collagen and flagellin degradation, TLR5 evasion, and human lung tissue inflammation.
Phosphonate zinc-binding inhibitors targeting Legionella ProA curtailed virulence by limiting collagen IV and flagellin degradation, restoring TLR5 signaling, and reducing PMN-driven inflammation in human lung tissue explants. Co-crystallization supports specific engagement of ProA, positioning these compounds as lead pathoblockers adjunctive to antibiotics.
Impact: Introduces a virulence-targeted therapeutic strategy for severe pneumonia that may reduce tissue damage and respiratory failure risk independent of bacterial killing.
Clinical Implications: If translated in vivo, adjunctive ProA inhibition could limit lung injury and improve outcomes in Legionnaires’ disease, especially in high-burden or antibiotic-delayed scenarios.
Key Findings
- Phosphonate inhibitor reduced ProA-dependent cleavage of host collagen IV and bacterial flagellin.
- Inhibitors mitigated immune evasion from TLR5-NF-κB signaling and decreased PMN-mediated inflammation in human lung tissue explants.
- ProA co-crystallization data support specific target engagement, advancing pathoblocker development.
Methodological Strengths
- Multi-scale validation: biochemical assays, cellular systems, and human lung tissue explants.
- Structural confirmation via ProA co-crystallization supporting mechanism-based inhibition.
Limitations
- No in vivo efficacy, pharmacokinetics, or toxicity data; clinical translation remains untested.
- Potential for off-target metalloprotease effects and resistance not addressed.
Future Directions: Evaluate in vivo efficacy/safety, lung delivery, and synergy with antibiotics; define selectivity panel and resistance potential; progress to IND-enabling studies.
Legionnaires' disease is a severe pneumonia caused by the aquatic bacterium Legionella pneumophila. In recent years, the number of cases has continuously increased according to the distribution of aerosol-producing technologies, global warming, and demographic ageing, which elevates bacterial transmission, environmental cell counts and host susceptibility. Despite the availability of an antibiotic therapy, this treatment cannot eradicate the risk of irreversible symptoms or high mortality rates. The bacterial zinc metalloprotease ProA significantly contributes to life-threatening tissue damage in patients and hence promotes progression of the disease. We hypothesize that additional application of an inhibitory agent against this protease may reduce serious complications and the risk of respiratory failure until successful bacterial clearance. Here we present a newly designed set of zinc-binding compounds and evaluated their inhibitory effects on the versatile physiological activity of ProA during infection. We identified a potent phosphonate inhibitor, which reduces ProA-dependent cleavage of host collagen IV and bacterial flagellin, immune evasion from the TLR5-NF-κB pathway and PMN-mediated inflammation in human lung tissue explants (HLTEs). Based on efficacy at the biochemical, cellular and tissue levels and the results of ProA co-crystallizations, we conclude that the selected inhibitors represent promising lead structures for the future development of clinically applicable pathoblockers against Legionnaires' disease.
3. Durvalumab after concurrent chemoradiotherapy for sensitizing epidermal growth factor receptor-mutant stage III non-small cell lung cancer: A Japanese Real-World data analysis.
In a 48-center Japanese cohort with PSM, consolidation durvalumab after CCRT significantly prolonged PFS versus CCRT alone (26.8 vs 11.1 months; HR 0.52). Severe EGFR-TKI adverse events did not differ overall, though early post-durvalumab osimertinib tended to increase grade ≥3 pneumonitis.
Impact: Addresses a key practice gap by providing real-world evidence supporting durvalumab after CCRT in EGFR-mutant stage III NSCLC, an area with prior uncertainty.
Clinical Implications: Durvalumab can be considered after CCRT in EGFR-mutant stage III NSCLC to prolong PFS, with careful coordination of subsequent EGFR-TKI timing to mitigate pneumonitis risk.
Key Findings
- After propensity score matching, durvalumab significantly prolonged PFS vs CCRT alone (26.8 vs 11.1 months; HR 0.52; p = 0.005).
- No significant difference in CTCAE grade ≥3 adverse events with EGFR-TKIs overall between groups.
- Early initiation of osimertinib after durvalumab tended to increase grade ≥3 pneumonitis.
Methodological Strengths
- Multi-institutional cohort with propensity score matching to reduce confounding.
- Clear, clinically meaningful endpoint (PFS) with robust hazard ratio and confidence intervals.
Limitations
- Retrospective design with potential residual confounding; OS effect not established.
- Generalizability beyond Japanese centers and across EGFR mutation subtypes may be limited.
Future Directions: Prospective trials to validate survival benefit and define optimal sequencing/timing with EGFR-TKIs; biomarker analyses to identify patients most likely to benefit.
INTRODUCTION: In locally advanced epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), the efficacy and safety of durvalumab after concurrent chemoradiotherapy (CCRT) remain controversial. METHODS: In this retrospective cohort study, we analyzed treatment outcomes in patients with unresectable stage III sensitizing EGFR-mutant NSCLC who underwent and completed CCRT without progression between July 2015 and June 2022 from 48 institutions in Japan. Patients with confirmed EGFR mutations after recurrence were excluded. Comparisons between groups were conducted using a cohort extracted through propensity score matching (PSM). The primary outcome was progression-free survival (PFS). The secondary outcomes were overall survival (OS) and safety of EGFR-tyrosine kinase inhibitor (TKIs) after durvalumab treatment. RESULTS: Out of 162 eligible patients, 106 received consolidation durvalumab following CCRT and 56 did not. After PSM, 56 patients were matched to the durvalumab and CCRT alone groups. The median PFS was significantly longer in patients treated with durvalumab than in those treated with CCRT alone (26.8 months [95% confidence interval [CI], 13.9-NA] vs. 11.1 months [95% CI, 9.0-18.2]; hazard ratio [HR], 0.52 [95% CI, 0.33-0.83]; p = 0.005). While early osimertinib administration following durvalumab tended to increase Common Terminology Criteria for Adverse Events (CTCAE) grade ≥ 3 pneumonitis, there was no significant difference in the frequency of CTCAE grade ≥ 3 adverse events with EGFR-TKIs between the groups (23.5 % vs. 20.8 %). CONCLUSIONS: Durvalumab administration following CCRT prolongs PFS in patients with locally advanced EGFR-mutant NSCLC. Durvalumab can be safely administered if the timing of subsequent osimertinib is carefully managed.